News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,126 Results
Type
Article (2577)
Company Profile (45)
Press Release (37503)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (14194)
Career Advice (78)
Deals (2108)
Drug Delivery (9)
Drug Development (4152)
Employer Resources (10)
FDA (448)
Job Trends (782)
News (20287)
Policy (1057)
Tag
Academia (145)
Allergies (7)
Alliances (3492)
ALS (6)
Alzheimer's disease (59)
Antibody-drug conjugate (ADC) (28)
Approvals (452)
Artificial intelligence (31)
Autoimmune disease (8)
Automation (2)
Bankruptcy (12)
Best Places to Work (476)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (29)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (45)
Cancer (325)
Cardiovascular disease (10)
Career advice (66)
Career pathing (1)
CAR-T (31)
CDC (1)
Cell therapy (81)
Cervical cancer (2)
Clinical research (3444)
Collaboration (199)
Company closure (2)
Compensation (104)
COVID-19 (186)
CRISPR (11)
C-suite (112)
Cystic fibrosis (7)
Data (419)
Denatured (6)
Depression (11)
Diabetes (17)
Diagnostics (488)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (36)
Drug pricing (10)
Duchenne muscular dystrophy (40)
Earnings (4500)
Editorial (6)
Employer branding (1)
Employer resources (8)
Events (6406)
Executive appointments (134)
FDA (594)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (167)
Gene editing (32)
Generative AI (1)
Gene therapy (55)
GLP-1 (63)
Government (158)
Guidances (24)
Healthcare (712)
HIV (1)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Immuno-oncology (14)
Indications (4)
Infectious disease (198)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (25)
Interviews (7)
IPO (1003)
IRA (7)
Job creations (293)
Job search strategy (62)
JPM (4)
Kidney cancer (6)
Labor market (11)
Layoffs (51)
Leadership (3)
Legal (215)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (4)
Manufacturing (52)
MASH (14)
Medical device (314)
Medtech (315)
Mergers & acquisitions (1220)
Metabolic disorders (72)
Multiple sclerosis (22)
Neurodegenerative disease (27)
Neuropsychiatric disorders (10)
Neuroscience (164)
NextGen: Class of 2026 (353)
Non-profit (155)
Now hiring (11)
Obesity (32)
Opinion (17)
Ovarian cancer (17)
Pain (27)
Pancreatic cancer (21)
Parkinson's disease (11)
Partnered (4)
Patents (53)
Patient recruitment (25)
Peanut (1)
People (5878)
Pharmaceutical (5)
Phase 1 (1479)
Phase 2 (1703)
Phase 3 (916)
Pipeline (390)
Policy (16)
Postmarket research (30)
Preclinical (640)
Press Release (2)
Prostate cancer (7)
Psychedelics (3)
Radiopharmaceuticals (14)
Rare diseases (62)
Real estate (425)
Recruiting (5)
Regulatory (916)
Reports (7)
Research institute (151)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (5)
RSV (1)
Schizophrenia (16)
Series A (46)
Series B (20)
Service/supplier (2)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (497)
Stomach cancer (2)
Supply chain (4)
Tariffs (2)
The Weekly (3)
Vaccines (52)
Venture capital (15)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Last 7 days (39)
Last 30 days (137)
Last 365 days (2415)
2026 (211)
2025 (2443)
2024 (2614)
2023 (2867)
2022 (3757)
2021 (4048)
2020 (3474)
2019 (2061)
2018 (1555)
2017 (1796)
2016 (1627)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1334)
2010 (1181)
Location
Africa (44)
Alabama (3)
Arizona (18)
Asia (1947)
Australia (307)
California (1601)
Canada (241)
China (80)
Colorado (54)
Connecticut (16)
Delaware (6)
Europe (4016)
Florida (64)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (21)
India (2)
Indiana (60)
Japan (17)
Kansas (14)
Kentucky (1)
Maryland (48)
Massachusetts (568)
Michigan (14)
Minnesota (22)
Mississippi (2)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (133)
New York (80)
North Carolina (131)
Northern California (781)
Ohio (44)
Oklahoma (2)
Oregon (6)
Pennsylvania (109)
Puerto Rico (1)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (652)
Tennessee (4)
Texas (152)
United States (3204)
Utah (5)
Virginia (11)
Washington D.C. (3)
Washington State (95)
West Virginia (1)
Wisconsin (13)
40,126 Results for "rampart bioscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Rampart Closes Down Less Than 2 Years After Launch
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
January 9, 2026
·
1 min read
·
Tristan Manalac
Press Releases
South Rampart Pharma Announces New Study in Neurobiology of Pain Demonstrating How SRP-001 Delivers Central, Non-Toxic Pain Relief
July 29, 2025
·
5 min read
Biotech Beach
Rampart Bioscience Announces $85M Series A Financing to Develop Novel DNA-Based Medicines with Veteran Team
Rampart Bioscience, Inc., a biotechnology company developing next-generation biologics, announced an $85 million Series A financing to create medicines that aim to unburden patients from disease and their treatments.
October 24, 2023
·
4 min read
BioMidwest
South Rampart Pharma to Present at Biotech Showcase 2024
South Rampart Pharma, Inc. announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma, will present the latest clinical and scientific data on its lead clinical asset at Biotech Showcase 2024 on Tuesday, January 9.
January 3, 2024
·
3 min read
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
Crossject provides additional, clinically meaningful perspectives on ZEPIZURE® in light of its recently published bioequivalence study results and of the conclusions and hints by the authors of the RAMPART study1, a landmark double-blind randomized clinical trial comparing the efficacy of IM midazolam vs. IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics.
June 26, 2024
·
5 min read
Drug Development
South Rampart Pharma Publishes SRP-001’s Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports
South Rampart Pharma, Inc., announced the publication of a paper in Scientific Reports describing the manner in which SRP-001 works in the brain to alleviate pain and the results of a Phase 1 randomized controlled trial 1.
May 16, 2024
·
6 min read
South Rampart Pharma to Participate in Upcoming Investor Events
South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company’s executive team will be participating in the upcoming investor events throughout October 2023.
October 10, 2023
·
3 min read
Drug Development
South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials
South Rampart Pharma, Inc. announced today that it has successfully completed a Phase 1 trial (NCT05484414).
January 2, 2024
·
6 min read
South Rampart Pharma Further Expands Patent Portfolio for SRP-001 with Composition of Matter Patent in China
South Rampart Pharma, Inc. (“South Rampart” or the “Company”) today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart’s novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen.
July 6, 2023
·
2 min read
South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain
South Rampart Pharma, Inc. announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023.
November 1, 2023
·
5 min read
1 of 4,013
Next